NMDP BioTherapies To Present Data at ISCT 2024 on the Stability of Infectious Disease Marker Analytes During Donor Qualification for Allogeneic Cell Therapies

By Investor Empires On May 28, 2024

The study, jointly conducted by researchers from Labor Quade and Johns Hopkins University School of Medicine, analyzed the long-term stability of IDM analytes in non-centrifuged peripheral blood samples to allow for increased flexibility in processing donor samples. The study results indicate that the widespread use of blood processing parameters developed to measure metabolites appears to create artificially stringent pre-analytical requirements for IDM testing.

MINNEAPOLIS — NMDP BioTherapies℠ (formerly Be The Match BioTherapies), a leader in supporting cell and gene therapy development, will present a poster at this year's International Society for Cell and Gene Therapy Annual Meeting in Vancouver, Canada (ISCT 2024) Study Results of the Effects of Delayed Blood Treatment Al-Kamil on the stability of analyzes of infectious disease markers while qualifying donors for allogeneic cell therapies. Study results suggest that leveraging blood processing parameters to stabilize metabolites may create artificially stringent pre-analytical requirements, such as timelines between sample collection and centrifugation.

Article content

“Sample processing delays when utilizing centralized testing laboratories can be a challenging reality in today’s donor qualification process for allogeneic cell therapies,” said Dr. Joy Aho, Director of Product Management at NMDP BioTherapies. “Our investigation, conducted in collaboration with Labor Quade and Johns Hopkins University School of Medicine, indicates that antibodies are stable and can be reliably tested for up to 120 hours after collection in serological tests and that qualitative results of nucleic acid testing are not materially negative.” It is affected by marked changes in copy number up to 120 h after assembly.

Poster display details

Title: The effect of delayed whole blood processing on the stability of analyzes of infectious disease markers during donor eligibility for allogeneic cell therapies
Label number: 857
When: Wednesday, May 29 from 7:00 to 8:30 pm
Location: Poster and Exhibition Hall, Vancouver Convention Centre, West Building

NMDP BioTherapies supports organizations creating next-generation cell and gene therapies. With access to donors and cord blood units from the NMDP℠ registry, the most diverse registry in the world, and an extensive collection network, NMDP BioTherapies provides a broad range of cell source options to developers of allogeneic gene and cell therapies so they can expand treatment options for patients with Life-threatening or debilitating illnesses.

About NMDP Biotherapeutics

NMDP BioTherapies is the only cell and gene therapy solutions provider offering customizable services to support the end-to-end cell therapy supply chain. Supported by NMDP℠'s industry-leading expertise and research partnership with CIBMTR® (International Center for Blood and Marrow Transplantation Research®), the organization designs solutions that advance cell and gene therapies around the world.

NMDP BioTherapies is dedicated to accelerating patients' access to life-saving cell and gene therapies by providing high-quality cell source materials from the NMDP℠ registry, the world's most diverse registry with more than 7 million potential blood stem cell donors. Through well-established relationships with blood apheresis, marrow collection and transplantation centers around the world, the organization develops, qualifies, trains and manages expansive collection networks for the development of cell therapies. NMDP BioTherapies utilizes a proven infrastructure consisting of regulatory compliance experts, managed logistics, and cell therapy supply chain case managers to transport and deliver regulatory-compliant life-saving therapies worldwide. Through CIBMTR, NMDP expands services beyond the cell therapy supply chain to include long-term follow-up tracking of FDA-approved CAR-T therapies.

For more information, follow NMDP BioTherapies on LinkedIn or Twitter.